Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 21;28(8):1630–1639. doi: 10.1038/s41591-022-01897-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — a After G47∆ therapy, 3 patients underwent craniotomy for tumor resection of regrown tumors (no. 1 and no. 17 at 4 months and no. 5 at 12 months after the last G47∆ administration). Infiltrating numbers of CD4 + and CD8 + lymphocytes remained abundantly increased in the two cases at 4 months and to some extent in the case at 12 months. Increased numbers of Foxp3+ cells were found in the two cases at 4 months and both underwent reoperation, but not found in the case at 12 months. Each is representative of 3 tissue samples. b Among 5 patients who underwent autopsy, 4 patients died of tumor progression (no. 1, no. 2, no. 5 and no. 16) and an infiltration of CD4+ and CD8+ lymphocytes and a low number of Foxp3+ cells persisted at autopsy 11 to 50 months after the last G47Δ administration. In patient no. 13 whose target lesion was well controlled at the time of death, necrosis and calcification, but no viable tumor cells, were found in the brain at autopsy 15 months after the last G47∆ administration. Each is representative of 3 tissue samples.